Japanese company Daiichi Sankyo filed a suit against Mylan for paten infringement on blood pressure product Azor®. Mylan said Daiichi Sankyo filed the suit in a New Jersey federal court Tuesday against its India-based unit Matrix Laboratories Ltd., citing Matrix's application earlier this year with the Food and Drug Administration to sell a generic version of Azor®. Azor® is a new combination of Amlodipine Besylate and Olmesartan Medoxomil, which has got approval in 2007. Azor® is having exclusivity till 2010 for its new combination. Innovator Company has listed only one patent (US 5,616,599) in Orange Book which covers Olmesartan Medoxomil as a product.
No comments:
Post a Comment